NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for ZR-75-1 Cells (Breast Carcinoma Cells, CRL-1500)
- Proprietary cationic lipids formulation
High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
Work in the presence of serum
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
Download PowerPoint presentation for ZR-75-1 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 93% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems ZR 751 Transfection Protocol: [PDF]
Download MSDS: [PDF]
ZR-75-1 Cell Line:
Breast cancer is considered the most prevalent malignancy in females and the fifth most common cause of cancer-related fatalities among women worldwide, representing a significant public health challenge. Metastatic breast cancer is the primary cause of death in patients diagnosed with breast cancer. Preclinical cell line models could help in discovering innovative treatment options for those affected. The ZR-75- cell line is established from a 63-year-old Caucasian female with ductal carcinoma of the breast. This cell line expresses an estrogen receptor and possesses a hypertriploid chromosome number (polyploidy). In addition to producing high levels of MUC-1 mucin mRNA, the ZR-75-1 cell line has a population doubling time of nearly 80 hours. ZR-75 is an epithelial cell line and is useful for studying the properties of tumors in breast cancer patients. Altogen Biosystems offers highly efficient pre-optimized transfection kits for the ZR-75-1 cell line.
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the ZR75 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in ZR-75-1 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into ZR-75-1 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6930)
- 1.5 ml (Catalog #6931)
- 1.5 ml CRISPR (Catalog #2203)
- 8.0 ml (Catalog #7094)